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Evidence for Extensive Locus Heterogeneity in Naxos Disease
To the Editor:
Naxos disease is a rare autosomal recessive disease that consists of an
associated triad of woolly hair, thickened palms and soles
(keratoderma), and heart involvement. The hair phenotype is
unique, characterized by congenital woolly, curly, rough, and light
colored scalp hair and sparse eyebrows. The nonepidermolytic
keratoderma appears during the ®rst years of life and involves mainly
pressure areas in the palms and soles. The heart manifestations appear
during the teenage years and are severe and progressive and may end
with arrhythmia and premature sudden death. The disease was
originally described in individuals from the Greek Island Naxos by
Protonotarios et al in 1986 and by Barker et al in 1998. In 1998,
Carvajal-Huerta reported patients from Guayaquil, Ecuador with a
similar autosomal recessive triad, with combined epidermolytic
palmoplantar keratoderma with woolly hair and dilated cardiomyo-
pathy, and described the skin manifestations. Another family with
the autosomal dominant association of nonepidermolytic palmo-
plantar keratoderma, woolly hair, and dilated right ventricle was
reported by Tosti et al (1994) in an Italian family. Recently, Coonar
et al (1998) mapped the gene for the Greek families (Naxos disease)
to 17q21, and a mutation in the plakoglobin gene was identi®ed as
responsible for the disease in the Greek families (McKoy et al, 2000).
In the Ecuadorian family, a mutation in the desmoplakin gene was
found to be responsible for the disease (Norgett et al, 2000). In this
study, we report the clinical ®ndings in two new Arab families with
Naxos disease originating from villages near Jerusalem. Importantly,
we have excluded both plakoglobin and desmoplakin as the
candidate genes in these families. Furthermore, we have analyzed
several other regions harboring candidate genes of interest, and
found no evidence for linkage.
The pedigree structures of the two families are shown in Fig 1(a,
b). The history and clinical examination of patients from families A
and B included the congenital appearance of woolly, curly, rough,
light colored scalp hair with sparse eyebrows, axillary, and pubic hair
(Fig 1c). Skin involvement included palmoplantar keratoderma
(Figs 1d, e) starting around age 3, as well as follicular keratosis on
extensor arms, shins, back, and cheeks, lichenoid papules mainly on
the lower shins and psoriasiform keratosis. A plantar skin biopsy
Figure 2. Immunohistochemical analysis of MIF expression in an extensive alopecia areata scalp biopsy. Tissue specimens were stained with
a Vector ABC staining kit using polyclonal antihuman MIF antibody. (A) Intense MIF staining was observed in the perifollicular-in®ltrated
lymphocytes of telogen hair follicles. Hair follicle MIF staining was also apparent. (B) No speci®c positive staining was observed using the tissue sample
stained with preimmune rabbit IgG. Scale bar: 50 mm.
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taken from affected individuals in these families showed two types of
keratoderma, speci®cally, epidermolytic in family A and non-
epidermolytic in family B. Furthermore, hair plucked from the
scalp of members of the two families revealed in affected members
plenty of trauma-related hair shaft abnormalities, including
longitudinal and oblique fractures, tapered hairs, trichorrhexis
nodosa like lesions, pseudomonilethrix, twisted and corkscrew-
like hair, without pili torti. Hairs were of different diameters and
some of them were curly. Electrocardiogram and echocardiogram
were performed, following the history of a sudden death at age 18 in
one affected family member (from family A) and complaints of
dizziness, syncope, and chest pain in other members. The
electrocardiogram demonstrated tachycardia in the young members
and different types of arrhythmia, including ventricular premature
beats, couplets, triplets, and nonsustained VT in older members. In
two members (family A, V-1, V-6) the echocardiogram showed
right ventricular dysplasia with right ventricular dilatation and
decreased function of the right and left ventricles. These clinical
observations provided the ®nal diagnosis of arrhytmogenic right
ventricular cardiomyopathy (ARVC).
Since all the affected members descended from consanguineous
couples, we hypothesized that the impaired gene must have arisen
from the same ancestral mutation in both alleles. Thus, hetero-
zygosity for the candidate gene/region was considered suf®cient for
exclusion of genetic linkage. Although both families originated from
the same geographic region in Israel, suggesting they might be
related, we elected to evaluate each candidate locus allowing for
genetic heterogeneity. First, we screened for mutations in the human
desmoplakin (NM_004415) and plakoglobin (AJ249711) genes
(Franke et al, 1989; Virata et al, 1992). Sequence analysis of each exon
and splice junctions of the desmoplakin and plakoglobin genes
(Whittock et al, 1999, 2000) from affected individuals revealed no
mutation in both genes compared with unrelated unaffected
individuals. Furthermore, we identi®ed several heterozygous
Figure 1. Pedigrees and clinical presentation of Naxos families A(a) and B(b). (a, b) Pedigrees of the two Naxos disease families from Israel.
Filled circles and squares represent affected females and males, respectively. A diagonal line through a symbol indicates a deceased individual. Double
lines are indicative of consanguinity. (c±e) Clinical presentation of the Naxos disease phenotype. Note in (c) the woolly and light colored, sparse hair
typical of affected patients. (d, e) The presence of marked palmoplantar hyperkeratosis is also a hallmark of this phenotype.
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sequence changes in the introns of affected individuals, supporting
the exclusion of these genes (data not shown).
Second, on the basis of the role of both desmoplakin and
plakoglobin in cell adhesion, several other genes coding for
components of the desmosomes or proteins involved in different
aspects of cell adhesion were considered as candidate genes for
the disease in our families. These included the genes coding for
type I and type II keratins on chromosomes 17 and 12,
respectively (Romano et al, 1988; Yoon et al, 1994; Aberle et al,
1995; Coonar et al, 1998), desmoyokin on 11q13.1 (Courseaux et al,
1996), and the desmocollin/desmoglein cluster on 18q12.1
(Arnemann et al, 1991). We also analyzed markers for plakophilin
1 at 1q32 (Cowley et al, 1997), plakophilin 2 at 12p13 (Bonne et al,
1998), and plakophilin 4 (or p0071) at 2q23-q31 (Hatzfeld and
Nachtsheim, 1996; Bonne et al, 1998). As the gene structures were
not available for each of these genes, we performed cosegregation
and homozygosity studies using microsatellite markers covering
these loci (Table I). As a result, none of the regions analyzed
showed cosegregation with the disease trait. Moreover, hetero-
zygosity in the affected members could be used to exclude the
regions on chromosomes 12, 17, and 18, harboring the keratins and
desmocollin/desmoglein gene clusters, respectively, as well as for the
chromosomal regions containing plakophilin 1, 2, and 4 as speci®ed
in Table I.
These ®ndings emphasize the hetergeneous genetic basis of
Naxos disease, which appears to segregate in a dominant manner as
well as the autosomal recessive forms (Tosti et al, 1994). Our future
work will be directed toward the evaluation of additional
desmosomal proteins, as well as conducting a whole genome scan
to ®nd regions homozygous by descent, and identify a novel
causative gene(s) underlying Naxos disease.
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Table I. Candidate genes excluded from linkage to Naxos disease
Gene/loci Chromosome location Markersa Distance (cM)
Plakophilin 1 1q32-q44 D1S2622
D1S477
D1S2686
214.08
215.17
216.46
Plakophilin 4 2q23-q31 D2S2241
D2S321
D2S284
156.92
157.55
161.81
Desmoplakin 6p24.3 D6S477
D6S470
D6S2434
9.18
18.22
25.08
Desmoyokin 11q13.1 D11S1765
D11S1883
61.78
65.05
Type II keratin 12q13.13 D12S1661
D12S390
D12S398
63.89
67.63
68.16
Plakophilin 2 12p13 D12S1053
GATA63D01
GATA123B12
51.99
53.64
55.50
Type I keratin 17q21.2 D17S800
D17S1789
62.01
63.09
Plakoglobin 17q21.1 D17S800
D17S1789
62.01
63.09
Desmocollins/desmogleins 18q12.1 D18S819
D18S847
GATA173A03
52.86
56.71
62.29
aPCR primers for the microsatellite markers were designed according to the sequences on the Genome Database and the Cooperative Human Linkage Center (http://
www.gdb.org; http://lpg.nci.nih.gov/CHLC).
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The Use of Histamine in Cancer Immunotherapy
To the Editor:
We read with interest the article by Hegyesi et al (2001) that reports
on the expression of histidine decarboxylase (HDC) in human
melanoma cells in vivo by western blotting and immunostaining on
tissue specimens from patients with primary melanoma (n = 20),
melanoma metastases (n = 5), nevi (n = 3), and normal skin
(n = 10). Furthermore, the report demonstrated that a HDC-
speci®c antisense oligonucleotide (ASO) suppressed melanoma cell
proliferation in two cell lines in vitro compared with a nonsense 18-
mer ASO. The authors speculate that endogenous histamine may
act as an autocrine growth factor, in¯uencing cell proliferation via
H2 histamine receptors (Burtin et al, 1988; Bolton et al, 2000), or
that melanoma growth is indirectly favored by locally produced
histamine that suppresses IFN-g production of surrounding
immune cells and therefore contributes to immune escape of
melanoma cells. Consequently, the authors argue, not only
traditional antihistaminics such as H2 histamine antagonists but
also ASO targeting HDC may soon became candidates for use in
melanoma treatment.
As some experimental ®ndings as well as current clinical
strategies are completely opposed, we would like to comment on
some of the reported statements of Hegyesi et al (2001).
First of all, we believe that the methodology employed to
determine HDC (e.g., western blot) is not adequate to draw any
®rm conclusions as it is long known that many tumors, including
melanoma, are surrounded by signi®cantly larger numbers of mast
cells containing histamine and HDC compared with nevi and
normal skin (Schadendorf et al, 1995). Furthermore, mast cell
counts are highly dependent on anatomical sites (Eady et al, 1979;
Cowen et al, 1979). Neither anatomical location nor the number of
mast cells is taken into account when tissues specimens are analyzed
by western blotting, thus leading to false hypotheses. Nevertheless,
the suppression of melanoma cell proliferation in two cell lines
in vitro is convincing. It cannot, however, be ruled out that other
genes critically involved in proliferation are affected which also
contribute to growth retardation. Our own data demonstrate that
histamine within a concentration range of 1±1000 mM had no
in¯uence on melanoma cell proliferation in vitro (D.S. and C.S.,
unpublished results).
Instead of using antihistamines (as was suggested by these
authors), histamine was introduced into the treatment of patients
with metastatic melanoma with some success in combination with
interleukin-2 (IL-2) (Hellstrand et al, 1994, 2000; Hauschild et al,
2001; Agarwala et al, 2002). Although the exact basis of action is
presently unclear, preclinical data suggest that histamine protects T
cells and natural killer cells against oxidative stress (Hansson et al,
1999) and leads to synergistic activation of lymphocytes in vitro.
Furthermore, histamine and IL-2 synergize in activating such
effects (Hellstrand et al, 2000). In pilot studies (Hellstrand et al,
1994, summarized in Hellstrand et al, 2000) as well as in a
prospective, randomized multicenter study (Agarwala et al, 2002), it
became clear that histamine dihydrochloride (Ceplene; previously
known as Maxamine) exhibits unexpected clinical bene®ts in
patients with metastatic melanoma of the liver (Hauschild et al,
2001; Agarwala et al, 2002), thus achieving for the ®rst time
signi®cant survival advantage for metastatic melanoma patients
using a combination of histamine and IL-2 in comparison with
patients treated with IL-2 only.
In conclusion, as histamine and HDC have been detected in
other cells besides melanoma cells, differentiating analytical
methods have to be chosen appropriately. Conclusion and
suggestions regarding possible clinical bene®ts have to be drawn
with utmost caution. Whether histamine dihydrochloride in
combination with IL-2 is really of bene®t in a subset of melanoma
patients is currently being tested in a con®rmatory prospective,
randomized, international multicenter trial in patients with liver
metastases. Results can be expected in 2±3 y.
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